113 related articles for article (PubMed ID: 17101825)
1. Inhibition by mitoxantrone of in vitro migration of immunocompetent cells: a possible mechanism for therapeutic efficacy in the treatment of multiple sclerosis.
Kopadze T; Dehmel T; Hartung HP; Stüve O; Kieseier BC
Arch Neurol; 2006 Nov; 63(11):1572-8. PubMed ID: 17101825
[TBL] [Abstract][Full Text] [Related]
2. Multiple sclerosis: Mitoxantrone promotes differential effects on immunocompetent cells in vitro.
Neuhaus O; Wiendl H; Kieseier BC; Archelos JJ; Hemmer B; Stüve O; Hartung HP
J Neuroimmunol; 2005 Nov; 168(1-2):128-37. PubMed ID: 16171875
[TBL] [Abstract][Full Text] [Related]
3. Cladribine impedes in vitro migration of mononuclear cells: a possible implication for treating multiple sclerosis.
Kopadze T; Döbert M; Leussink VI; Dehmel T; Kieseier BC
Eur J Neurol; 2009 Mar; 16(3):409-12. PubMed ID: 19175384
[TBL] [Abstract][Full Text] [Related]
4. Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis.
Leppert D; Waubant E; Bürk MR; Oksenberg JR; Hauser SL
Ann Neurol; 1996 Dec; 40(6):846-52. PubMed ID: 9007089
[TBL] [Abstract][Full Text] [Related]
5. Migration of T-cell subsets in multiple sclerosis and the effect of interferon-beta1a.
Dressel A; Mirowska-Guzel D; Gerlach C; Weber F
Acta Neurol Scand; 2007 Sep; 116(3):164-8. PubMed ID: 17714329
[TBL] [Abstract][Full Text] [Related]
6. Mitoxantrone does not restore the impaired suppressive function of natural regulatory T cells in patients suffering from multiple sclerosis. A longitudinal ex vivo and in vitro study.
Putzki N; Kumar M; Kreuzfelder E; Grosse-Wilde H; Diener HC; Limmroth V
Eur Neurol; 2009; 61(1):27-32. PubMed ID: 18948697
[TBL] [Abstract][Full Text] [Related]
7. In vitro study of matrix metalloproteinase/tissue inhibitor of metalloproteinase production by mesenchymal stromal cells in response to inflammatory cytokines: the role of their migration in injured tissues.
Tondreau T; Meuleman N; Stamatopoulos B; De Bruyn C; Delforge A; Dejeneffe M; Martiat P; Bron D; Lagneaux L
Cytotherapy; 2009; 11(5):559-69. PubMed ID: 19551542
[TBL] [Abstract][Full Text] [Related]
8. The effects of methylprednisolone and mitoxantrone on CCL5-induced migration of lymphocytes in multiple sclerosis.
Jalosinski M; Karolczak K; Mazurek A; Glabinski A
Acta Neurol Scand; 2008 Aug; 118(2):120-5. PubMed ID: 18336625
[TBL] [Abstract][Full Text] [Related]
9. Similar sensitivity of regulatory T cells towards CD95L-mediated apoptosis in patients with multiple sclerosis and healthy individuals.
Fritzsching B; Korporal M; Haas J; Krammer PH; Suri-Payer E; Wildemann B
J Neurol Sci; 2006 Dec; 251(1-2):91-7. PubMed ID: 17092518
[TBL] [Abstract][Full Text] [Related]
10. Specific central nervous system recruitment of HLA-G(+) regulatory T cells in multiple sclerosis.
Huang YH; Zozulya AL; Weidenfeller C; Metz I; Buck D; Toyka KV; Brück W; Wiendl H
Ann Neurol; 2009 Aug; 66(2):171-83. PubMed ID: 19705413
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of mitoxantrone in multiple sclerosis--what is known?
Neuhaus O; Kieseier BC; Hartung HP
J Neurol Sci; 2004 Aug; 223(1):25-7. PubMed ID: 15261556
[TBL] [Abstract][Full Text] [Related]
12. Mitoxantrone in multiple sclerosis.
Neuhaus O; Kieseier BC; Hartung HP
Adv Neurol; 2006; 98():293-302. PubMed ID: 16400840
[No Abstract] [Full Text] [Related]
13. [Effects of follicle stimulating hormone on proliferation, apoptosis, migration and invasion of ovarian carcinoma cells: an in vitro experiment].
Huang Y; Zhao YQ; Su M; Gao SJ; Jin HY; Feng YJ
Zhonghua Yi Xue Za Zhi; 2007 Sep; 87(35):2512-4. PubMed ID: 18067819
[TBL] [Abstract][Full Text] [Related]
14. Mitoxantrone induces cell death in peripheral blood leucocytes of multiple sclerosis patients.
Chan A; Weilbach FX; Toyka KV; Gold R
Clin Exp Immunol; 2005 Jan; 139(1):152-8. PubMed ID: 15606626
[TBL] [Abstract][Full Text] [Related]
15. Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial.
Minagar A; Alexander JS; Schwendimann RN; Kelley RE; Gonzalez-Toledo E; Jimenez JJ; Mauro L; Jy W; Smith SJ
Arch Neurol; 2008 Feb; 65(2):199-204. PubMed ID: 18071030
[TBL] [Abstract][Full Text] [Related]
16. Mitoxantrone treatment in multiple sclerosis induces TH2-type cytokines.
Vogelgesang A; Rosenberg S; Skrzipek S; Bröker BM; Dressel A
Acta Neurol Scand; 2010 Oct; 122(4):237-43. PubMed ID: 19925529
[TBL] [Abstract][Full Text] [Related]
17. Intravenous mitoxantrone and cyclophosphamide as second-line therapy in multiple sclerosis: an open-label comparative study of efficacy and safety.
Zipoli V; Portaccio E; Hakiki B; Siracusa G; Sorbi S; Amato MP
J Neurol Sci; 2008 Mar; 266(1-2):25-30. PubMed ID: 17870094
[TBL] [Abstract][Full Text] [Related]
18. In vitro spontaneous osteoclastogenesis of human peripheral blood mononuclear cells is not crucially dependent on T lymphocytes.
Vandooren B; Melis L; Veys EM; Tak PP; Baeten D
Arthritis Rheum; 2009 Apr; 60(4):1020-5. PubMed ID: 19333923
[TBL] [Abstract][Full Text] [Related]
19. A macrophage marker, Siglec-1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type I interferons and toll-like receptor agonists.
York MR; Nagai T; Mangini AJ; Lemaire R; van Seventer JM; Lafyatis R
Arthritis Rheum; 2007 Mar; 56(3):1010-20. PubMed ID: 17328080
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of mitoxantrone, as an initial therapy, in multiple sclerosis: experience in an Indian tertiary care setting.
Singhal BS; Geeta S; Hundalani SG; Menon S
Neurol India; 2009; 57(4):418-23. PubMed ID: 19770542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
